Investor Contact

Media & Investor Relations:
Roderick de Greef 
Chief Financial Officer
(425) 402 - 1400
rdegreef@BioLifeSolutions.com

Investor Relations

LHA Investor Relations
www.lhai.com
2121 Avenue of the Stars
Suite 2970
Los Angeles, CA 90067
Phone: 310-691-7100
Jody Cain: jcain@lhai.com

Transfer Agent

Broadridge Corporate Issuer Solutions, Inc. 
P.O. Box 1342
Brentwood, New York 11717
USA
(877) 830 - 4936
shareholder@broadridge.com

Investor Alerts

Register here to receive email notifications with updates about our press releases, stock price, SEC filings and more.

Press Releases

Cryomedical Sciences Changes Name to BioLife Solutions; Trading Symbol Changes to 'BLFS'
Reflects Company's Focus as Developer and Marketer of Cell Preservation Technology to Biotechnology Industry
PRNewswire-FirstCall
BINGHAMTON, N.Y.

Cryomedical Sciences, Inc. (BULLETIN BOARD: BLFS) announced that effective September 30, 2002, the Company has changed its name to BioLife Solutions, Inc. and will begin to trade under the new symbol, "BLFS."

The name and symbol change completes BioLife's restructuring, which began in May 2002, with the sale of the Company's cryosurgical assets, and reflects its renewed focus as a developer and marketer of proprietary cell preservation technology to biotechnology companies worldwide.

President and CEO John Baust, Ph.D., commented, "BioLife Solutions better reflects the refocus of the Company's resources on our founding HypoThermosol® technology, a line of customized preservation solutions which significantly prolong cell, tissue and organ viability. We believe we are well positioned to take advantage of the numerous opportunities in this important and emerging area of biomedical technology and are committed to bringing the Company to profitability."

About BioLife Solutions, Inc.

BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on the Company's proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. The expanding practice of cell and gene therapy has created a need for products that ensure the biological viability of mammalian cell and tissue material during transportation and storage. The HypoThermosol® and CryoStor™ products that the Company is selling today are a significant step forward in meeting these needs.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

For further information please contact: investors, Jill Bertotti, jill@allencaron.com, or media, Len Hall, len@allencaron.com, both of Allen & Caron Inc, +1-949-474-4300, for Cryomedical Sciences, Inc.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X30127839

SOURCE: Cryomedical Sciences, Inc.

CONTACT: investors, Jill Bertotti, jill@allencaron.com, or media, Len
Hall, len@allencaron.com, both of Allen & Caron Inc, +1-949-474-4300, for
Cryomedical Sciences, Inc.